

News Releases

All Years

Search

Go

[Advanced Search](#)

SEP 3, 2019

Inhibrx Reports Phase 1 Dose Escalation Results of INBRX-109, a Multivalent Agonist of Death Receptor 5

MAY 21, 2019

Inhibrx Announces \$40M Investment from Viking Global Investors

FEB 19, 2019

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody

JAN 7, 2019

bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies

DEC 6, 2018

Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)

Show 5  per page

[«](#) [1](#) [...](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [»](#)



